Vaccine News and Research

Latest Vaccine News and Research

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.

29 Mar 2010

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today it has entered into exclusive license, supply and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company. Pursuant to the agreements, Parenteral is authorized to register, supply and distribute Sinovac's Anflu (seasonal influenza vaccine) and PANFLU.1 (H1N1 vaccine) to the government of India and private market in India. Currently, the registration process is ongoing in India.

29 Mar 2010

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical Corporation today reported financial results for the quarter and year ended December 31, 2009.

29 Mar 2010

Rift Valley Fever on the rise

Rift Valley fever (RVF) is a viral infection transmitted by mosquitoes that mainly affects animals and livestock but may also infect humans. It can lead to high rates of death and disease. While mild forms of the disease can cause fever, muscle and joint pains, headaches, loss of appetite etc., the severe form can affect the eyes, cause meningitis, severe bleeding and even death.

29 Mar 2010

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

29 Mar 2010

Study provides new clues to obesity epidemic

In a newly published study, scientists from The Scripps Research Institute have shown for the first time that the same molecular mechanisms that drive people into drug addiction are behind the compulsion to overeat, pushing people into obesity.

29 Mar 2010

TB-causing bacteria can hijack fat metabolism to drive progression of the disease

The factors instrumental in triggering latent tuberculosis infection to progress into active disease have long remained elusive to researchers. New insight into the mystery is provided by Professor David Russell, speaking at the Society for General Microbiology's spring meeting in Edinburgh today. His work could help develop innovative strategies for treating the disease.

29 Mar 2010

Role Tregs play in therapeutic HIV vaccines

Like a skittish driver slamming the brakes, a special class of T cells may be limiting the effectiveness of therapeutic vaccines for HIV by slowing the immune system response too soon, report University of Pittsburgh health science researchers in the current issue of PLoS ONE. Their study, the first to look at the role of regulatory T cells in therapeutic HIV vaccines, may help researchers improve the efficacy of such vaccines by devising methods to circumvent the braking mechanism of these cells.

27 Mar 2010

NIH awards $15M grant to UMDNJ-New Jersey Medical School

For the second time in less than one month, the University of Medicine and Dentistry of New Jersey-New Jersey Medical School has been awarded a coveted $15 million grant by the National Institutes of Health.

27 Mar 2010

Senate briefing to discuss TB and drug-resistant TB

A Senate briefing today will discuss TB and drug-resistant TB, including multidrug-resistant TB (MDR-TB) and extensively drug resistant (XDR-TB), the impact on global health and the current state of surveillance, diagnosis and treatment around the world.

26 Mar 2010

PAHO documents increase in dengue fever cases in Latin America

Countries in Latin America "are bracing this year for a particularly virulent outbreak of the mosquito-borne tropical disease" known as dengue fever, after reports show an increase in the number of cases recorded this year, Agence France-Presse reports. "The Pan-American Health Organization (PAHO) said so far it has logged some 146,000 cases in the first three months of the year, of which 79 have been fatal. This time last year there were some 79,000 cases of dengue reported, with 26 deaths," the news service writes.

26 Mar 2010

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, providing information on rebound viral genetic diversity in HIV patients treated with the personalized immunotherapy following antiretroviral therapy (ART) interruption. The data were discussed in a poster session at the Keystone Symposia Global Health Series HIV Vaccines meeting, held March 21-26, 2010 in Banff, Canada.

26 Mar 2010

Positive results from Stage A pivotal study of 2009 A/H1N1 VLP pandemic influenza vaccine

Novavax, Inc. announced today positive results from the entire 1,000 subject Stage A of its two-stage pivotal study evaluating the safety and immunogenicity of Novavax's unadjuvanted 2009 A/H1N1 virus-like particle pandemic influenza vaccine.

26 Mar 2010

New research may help advance treatment strategies for common liver disease

A research article published in the journal PloS Pathogens could lead to improvements in the production of vaccines for hepatitis A, the most widespread viral disease in the world.

26 Mar 2010

UNAIDS Executive Director calls for 'serious attention to TB' on World TB Day

In a statement marking World Tuberculosis Day, UNAIDS Executive Director Michel Sidibe "warned Wednesday that double infections of HIV and TB could become the next new epidemic," the Associated Press reports. Sidibe said, "I'm calling for serious attention to TB, and serious attention to TB-HIV co-infection" (Corder, 3/24).

25 Mar 2010

Glaxosmithkline, Pfizer will supply 60M doses of reduced-price pneumococcal vaccines to developing countries over 10 years, GAVI says

The GAVI Alliance on Tuesday formally announced that drugmakers GlaxoSmithKline and Pfizer had signed off on a "10-year deal … to supply 60 million doses a year of cut-price pneumococcal vaccines to developing nations," Reuters reports.

25 Mar 2010

Study on zebrafish regenerate tissues links human heart implications

In a paper published in the March 25, 2010 issue of Nature, researchers working at the Salk Institute for Biological Studies and the Center of Regenerative Medicine in Barcelona (CMRB) identified a fish heart cell population that is the source of this astonishing healing feat, a finding that could provide insight into how mammalian hearts might be coaxed into repairing themselves after injury brought on by heart attack.

25 Mar 2010

Clinic sites seek gay men to participate in HIV vaccine study

Clinic sites in 13 cities across the U.S. are looking for a total of 1,350 HIV-negative gay men to participate in the latest HIV vaccine study from the HIV Vaccine Trials Network (HVTN). And they're using social media to help reach these individuals where they are, which, these days, is increasingly online.

25 Mar 2010

Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference

ImmunoCellular Therapeutics announced today that Manish Singh, Ph.D., President and CEO, will be presenting at the Cancer Stem Cells Conference, a leading industry event, on Wednesday, March 24th at 2:00 p.m. eastern time.

25 Mar 2010

Experimental vaccine can help delay IBD and colon cancer

An experimental vaccine against an abnormal protein found in some tumors has the potential to delay the onset of inflammatory bowel disease (IBD) and in turn prevent progression to colon cancer, according to researchers at the University of Pittsburgh School of Medicine.

25 Mar 2010

Vaccine News and Research

Latest Vaccine News and Research

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Rift Valley Fever on the rise

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Study provides new clues to obesity epidemic

TB-causing bacteria can hijack fat metabolism to drive progression of the disease

Role Tregs play in therapeutic HIV vaccines

NIH awards $15M grant to UMDNJ-New Jersey Medical School

Senate briefing to discuss TB and drug-resistant TB

PAHO documents increase in dengue fever cases in Latin America

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Positive results from Stage A pivotal study of 2009 A/H1N1 VLP pandemic influenza vaccine

New research may help advance treatment strategies for common liver disease

UNAIDS Executive Director calls for 'serious attention to TB' on World TB Day

Glaxosmithkline, Pfizer will supply 60M doses of reduced-price pneumococcal vaccines to developing countries over 10 years, GAVI says

Study on zebrafish regenerate tissues links human heart implications

Clinic sites seek gay men to participate in HIV vaccine study

Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference

Experimental vaccine can help delay IBD and colon cancer

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in